{"id":{"repo_id":"edinburgh","oai_identifier":"oai:era.ed.ac.uk:1842/42226"},"canonical_url":"https://search.ndltd.org/etd/edinburgh/oai:era.ed.ac.uk:1842/42226","repository":{"repo_id":"edinburgh","name":"University of Edinburgh","base_url":"https://era.ed.ac.uk/server/oai/request"},"display":{"title":"Investigating the clinical correlation between sporadic Creutzfeldt Jakob disease and presence of other neurodegenerative pathologies","abstract":"INTRODUCTION: Sporadic Creutzfeldt Jakob Disease (sCJD) is a rapidly progressive and fatal neurodegenerative disorder. Age-specific mortality rates for sCJD have increased up to 65-79 years over the past four decades. Of interest is an apparent reduced incidence at 80 and over. It has been hypothesised that the apparent decline in incidence of sCJD in older adults could be due to the inhibitory effects of the Alzheimer’s disease (AD) associated amyloid β-protein(Aβ) on prion propagation. METHODS: Retrospective case note review of cases of definite sCJD over a 3 year period from 2016-2018. Cases evaluated for the presence of additional neurodegenerative pathology on neuropathological examination of brain material. Specifically Aβ, tau, α-synuclein and cerebral amyloid angiopathy (CAA). RESULTS: 123 cases of definite sCJD were identified in the UK between 2016-2018. 56/112 (50%) of cases show evidence of co-existing pathology in addition to sCJD. Cases with co-pathology had a higher age at death by 6.3 years (95% CI (2.95, 9.59 ) p<0.001). Median disease duration from onset of symptoms was shorter in the sCJD plus co-pathology group when compared to the sCJD only group by 1.3 months (p=0.205). Co-pathology cases were more likely to present with cognitive decline or neuropsychiatric features (p=0.025). Co-pathology cases were slightly more likely to test negative for CSF RT-QuIC and MRI. Patients with co-pathology were slightly less likely to be assessed by the National CJD Research and Surveillance Unit in life. CONCLUSION: This data suggests a potential association between the presence of other neurotoxic proteins in the brain of sCJD patients with older age of onset and distinct presenting symptoms. Findings have implications for clinical care and surveillance of sCJD in older adults.","abstract_html":"INTRODUCTION: Sporadic Creutzfeldt Jakob Disease (sCJD) is a rapidly progressive and fatal neurodegenerative disorder. Age-specific mortality rates for sCJD have increased up to 65-79 years over the past four decades. Of interest is an apparent reduced incidence at 80 and over. It has been hypothesised that the apparent decline in incidence of sCJD in older adults could be due to the inhibitory effects of the Alzheimer’s disease (AD) associated amyloid β-protein(Aβ) on prion propagation. METHODS: Retrospective case note review of cases of definite sCJD over a 3 year period from 2016-2018. Cases evaluated for the presence of additional neurodegenerative pathology on neuropathological examination of brain material. Specifically Aβ, tau, α-synuclein and cerebral amyloid angiopathy (CAA). RESULTS: 123 cases of definite sCJD were identified in the UK between 2016-2018. 56/112 (50%) of cases show evidence of co-existing pathology in addition to sCJD. Cases with co-pathology had a higher age at death by 6.3 years (95% CI (2.95, 9.59 ) p&lt;0.001). Median disease duration from onset of symptoms was shorter in the sCJD plus co-pathology group when compared to the sCJD only group by 1.3 months (p=0.205). Co-pathology cases were more likely to present with cognitive decline or neuropsychiatric features (p=0.025). Co-pathology cases were slightly more likely to test negative for CSF RT-QuIC and MRI. Patients with co-pathology were slightly less likely to be assessed by the National CJD Research and Surveillance Unit in life. CONCLUSION: This data suggests a potential association between the presence of other neurotoxic proteins in the brain of sCJD patients with older age of onset and distinct presenting symptoms. Findings have implications for clinical care and surveillance of sCJD in older adults.","abstract_has_math":false,"creators":["Lumsden, Jane Rebecca"],"institution":"The University of Edinburgh","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Pal, Suvankar","Smith, Colin"],"committee_chairs":[],"committee_members":[],"year":2024,"date_issued":"2024-09-25","date_published":"2024-09-25","updated_at":"2026-11-18T19:26:33Z","subjects":["neurodegenerative pathologies","Sporadic Creutzfeldt Jakob Disease (sCJD)","Age-specific mortality","Alzheimer’s disease (AD)","amyloid β-protein(Aβ)","prion propagation","neurotoxic proteins"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://dx.doi.org/10.7488/era/4947"],"render_values":[{"text":"http://dx.doi.org/10.7488/era/4947","href":"http://dx.doi.org/10.7488/era/4947","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/1842/42226","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/1842/42226","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://era.ed.ac.uk/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Aera.ed.ac.uk%3A1842%2F42226","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Pal, Suvankar","Smith, Colin"]},{"key":"dc:creator","label":"Author","values":["Lumsden, Jane Rebecca"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2024-09-25T15:20:08Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2024-09-25T15:20:08Z"]},{"key":"dc:date.issued","label":"Date","values":["2024-09-25"]},{"key":"dc:publisher","label":"Institution","values":["The University of Edinburgh"]},{"key":"dc:relation.hasversion","label":"Dc Relation Hasversion","values":["Conference abstract published: Prion 2019; 13:35. Why is there a decline in the incidence of sporadic Creutzfeldt Jakob Disease in the older adult population? Lumsden J, Will B, Smith C, Pal S"]},{"key":"dc:type","label":"Dc Type","values":["Thesis or Dissertation"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["Doctoral"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["MD Doctor of Medicine"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["neurodegenerative pathologies","Sporadic Creutzfeldt Jakob Disease (sCJD)","Age-specific mortality","Alzheimer’s disease (AD)","amyloid β-protein(Aβ)","prion propagation","neurotoxic proteins"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/1842/42226","http://dx.doi.org/10.7488/era/4947"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["INTRODUCTION: Sporadic Creutzfeldt Jakob Disease (sCJD) is a rapidly progressive and fatal neurodegenerative disorder. Age-specific mortality rates for sCJD have increased up to 65-79 years over the past four decades. Of interest is an apparent reduced incidence at 80 and over. It has been hypothesised that the apparent decline in incidence of sCJD in older adults could be due to the inhibitory effects of the Alzheimer’s disease (AD) associated amyloid β-protein(Aβ) on prion propagation. METHODS: Retrospective case note review of cases of definite sCJD over a 3 year period from 2016-2018. Cases evaluated for the presence of additional neurodegenerative pathology on neuropathological examination of brain material. Specifically Aβ, tau, α-synuclein and cerebral amyloid angiopathy (CAA). RESULTS: 123 cases of definite sCJD were identified in the UK between 2016-2018. 56/112 (50%) of cases show evidence of co-existing pathology in addition to sCJD. Cases with co-pathology had a higher age at death by 6.3 years (95% CI (2.95, 9.59 ) p<0.001). Median disease duration from onset of symptoms was shorter in the sCJD plus co-pathology group when compared to the sCJD only group by 1.3 months (p=0.205). Co-pathology cases were more likely to present with cognitive decline or neuropsychiatric features (p=0.025). Co-pathology cases were slightly more likely to test negative for CSF RT-QuIC and MRI. Patients with co-pathology were slightly less likely to be assessed by the National CJD Research and Surveillance Unit in life. CONCLUSION: This data suggests a potential association between the presence of other neurotoxic proteins in the brain of sCJD patients with older age of onset and distinct presenting symptoms. Findings have implications for clinical care and surveillance of sCJD in older adults."]},{"key":"dc:title","label":"Title","values":["Investigating the clinical correlation between sporadic Creutzfeldt Jakob disease and presence of other neurodegenerative pathologies"]},{"key":"others:access_status","label":"Others Access Status","values":["open.access"]}]}],"canonical_facts":{"dc:contributor.advisor":["Pal, Suvankar","Smith, Colin"],"dc:creator":["Lumsden, Jane Rebecca"],"dc:date.accessioned":["2024-09-25T15:20:08Z"],"dc:date.available":["2024-09-25T15:20:08Z"],"dc:date.issued":["2024-09-25"],"dc:description.abstract":["INTRODUCTION: Sporadic Creutzfeldt Jakob Disease (sCJD) is a rapidly progressive and fatal neurodegenerative disorder. Age-specific mortality rates for sCJD have increased up to 65-79 years over the past four decades. Of interest is an apparent reduced incidence at 80 and over. It has been hypothesised that the apparent decline in incidence of sCJD in older adults could be due to the inhibitory effects of the Alzheimer’s disease (AD) associated amyloid β-protein(Aβ) on prion propagation. METHODS: Retrospective case note review of cases of definite sCJD over a 3 year period from 2016-2018. Cases evaluated for the presence of additional neurodegenerative pathology on neuropathological examination of brain material. Specifically Aβ, tau, α-synuclein and cerebral amyloid angiopathy (CAA). RESULTS: 123 cases of definite sCJD were identified in the UK between 2016-2018. 56/112 (50%) of cases show evidence of co-existing pathology in addition to sCJD. Cases with co-pathology had a higher age at death by 6.3 years (95% CI (2.95, 9.59 ) p<0.001). Median disease duration from onset of symptoms was shorter in the sCJD plus co-pathology group when compared to the sCJD only group by 1.3 months (p=0.205). Co-pathology cases were more likely to present with cognitive decline or neuropsychiatric features (p=0.025). Co-pathology cases were slightly more likely to test negative for CSF RT-QuIC and MRI. Patients with co-pathology were slightly less likely to be assessed by the National CJD Research and Surveillance Unit in life. CONCLUSION: This data suggests a potential association between the presence of other neurotoxic proteins in the brain of sCJD patients with older age of onset and distinct presenting symptoms. Findings have implications for clinical care and surveillance of sCJD in older adults."],"dc:identifier.uri":["https://hdl.handle.net/1842/42226","http://dx.doi.org/10.7488/era/4947"],"dc:language.iso":["en"],"dc:publisher":["The University of Edinburgh"],"dc:relation.hasversion":["Conference abstract published: Prion 2019; 13:35. Why is there a decline in the incidence of sporadic Creutzfeldt Jakob Disease in the older adult population? Lumsden J, Will B, Smith C, Pal S"],"dc:subject":["neurodegenerative pathologies","Sporadic Creutzfeldt Jakob Disease (sCJD)","Age-specific mortality","Alzheimer’s disease (AD)","amyloid β-protein(Aβ)","prion propagation","neurotoxic proteins"],"dc:title":["Investigating the clinical correlation between sporadic Creutzfeldt Jakob disease and presence of other neurodegenerative pathologies"],"dc:type":["Thesis or Dissertation"],"dc:type.qualificationlevel":["Doctoral"],"dc:type.qualificationname":["MD Doctor of Medicine"],"others:access_status":["open.access"]},"updated_at":"2026-11-18T19:26:33Z"}